In an open-label randomised trial of 232 adults with migraine, transcutaneous supraorbital nerve stimulation failed non-inferiority to topiramate 25 mg for responder rate (20.6% vs 33.9%) but had fewer adverse events (4.3% vs 22.4%).
RCTn = 232
Ye et al. Efficacy and safety of transcutaneous supraorbital nerve stimulation versus topiramate for migraine prevention: a non-inferiority randomized trial